Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Raises $7.1M in Series C Round of Financing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Companion diagnostics developer Biodesix today said that it has raised $7.1 million in a Series C round of financing, which will fund further development of its VeriStrat test.

The new round was led by existing investors, who provided $5.1 million in the round. The money will go toward ongoing commercialization of VeriStrat, a serum proteomic-based test to help guide treatment of patients with non-small cell lung cancer.

"This new investment will allow us to broaden and accelerate commercialization activities for VertiStrat, including expanding our studies of VeriStrat's utility with new drug combinations that can significantly improve outcomes for lung cancer patients," Biodesix CEO David Brunel said in a statement.

The Broomfield, Colo.-based company also said that it recently received $1.4 million in grants from the IRS' Qualified Therapeutic Discovery Program, which provides funds to small businesses with promising technologies for developing new therapies directed at unmet medical issues.

The grants will be used to advance development of six molecular diagnostic programs in oncology and autoimmune diseases, Biodesix said. Each of the programs leverages the firm's ProTS platform, which uses MALDI-MS as a diagnostic tool.

The QTDP funds and the $7.1 Series C round will also go toward clinical confirmation of VeriStrat with additional targeted oncology therapies and other tumor types such as colorectal, breast, and head and neck cancers, the company said.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.